Healthcare

 RSV vaccines to receive review by FDA advisory panel

By Abigail Adcox
Published February 22, 2023 9:18pm ET
Add Washington Examiner on Google
 RSV vaccines to receive review by FDA advisory panel
A vaccine advisory committee for the Food and Drug Administration will review whether to recommend two vaccines for respiratory syncytial virus for approval next week as pharmaceutical giant Pfizer and rival drug manufacturer GSK vie to have the first RSV vaccine to hit the U.S. market. The Vaccines and Related Biological Products Advisory Committee, the […]


A vaccine advisory committee for the Food and Drug Administration will review whether to recommend two vaccines for respiratory syncytial virus for approval next week as pharmaceutical giant Pfizer and rival drug manufacturer GSK vie to have the first RSV vaccine to hit the U.S. market.

Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.

Tag:

FDA Pfizer Vaccines